Capillary leak syndrome cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Capillary leak syndrome}} | {{Capillary leak syndrome}} | ||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [https://www.wikidoc.org/index.php/User:Hassan_M M. Hassan, M.B.B.S] | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [https://www.wikidoc.org/index.php/User:Hassan_M M. Hassan, M.B.B.S] | ||
| Line 11: | Line 14: | ||
|- | |- | ||
| colspan="2" | | | colspan="2" | | ||
=== '''Endothelial signal transduction''' === | ==='''Endothelial signal transduction'''=== | ||
|- | |- | ||
|'''[[Bevacizumab]]''' | |'''[[Bevacizumab]]''' | ||
| | | | ||
* [[Bevacizumab]] costs in 2014 averaged around $9324 for a total duration of 8 weeks | *[[Bevacizumab]] costs in 2014 averaged around $9324 for a total duration of 8 weeks | ||
* The average price of the drug was $66.60 per 10 mg given at 5 mg given every 2 weeks <ref name="pmid26380601">{{cite journal| author=| title=Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer. | journal=Am Health Drug Benefits | year= 2015 | volume= 8 | issue= Spec Issue | pages= 10-2 | pmid=26380601 | doi= | pmc=4570073 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26380601 }}</ref> | *The average price of the drug was $66.60 per 10 mg given at 5 mg given every 2 weeks<ref name="pmid26380601">{{cite journal| author=| title=Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer. | journal=Am Health Drug Benefits | year= 2015 | volume= 8 | issue= Spec Issue | pages= 10-2 | pmid=26380601 | doi= | pmc=4570073 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26380601 }}</ref><br /> | ||
|- | |||
|'''[[Epoprostenol]]''' | |||
| | |||
* Over a two 6-month period, [[epoprostenol]] was estimated to cost around $19,483.48. This did not include equipment use of $283.25 which brought the total cost near $19,766.73<ref name="pmid10144080">{{cite journal| author=Petros AJ, Turner SC, Nunn AJ| title=Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension. | journal=J Pharm Technol | year= 1995 | volume= 11 | issue= 4 | pages= 163-6 | pmid=10144080 | doi=10.1177/875512259501100409 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10144080 }}</ref> | |||
<br /> | <br /> | ||
|- | |- | ||
|'''[[Theophylline]] + [[Terbutaline]]''' | |'''[[Theophylline]] + [[Terbutaline]]''' | ||
| | | | ||
* [[Theophylline]] | *Due to the risk of toxicity, [[Theophylline]] requires increased monitoring. Due to this, costs can average around $121.40 per patient per month <ref name="pmid8449051">{{cite journal| author=Jubran A, Gross N, Ramsdell J, Simonian R, Schuttenhelm K, Sax M | display-authors=etal| title=Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study. | journal=Chest | year= 1993 | volume= 103 | issue= 3 | pages= 678-84 | pmid=8449051 | doi=10.1378/chest.103.3.678 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8449051 }}</ref> | ||
* [[Terbutaline]] | *Compared to other [[Tocolytic|tocolytics]], [[Terbutaline]] required increased monitoring due to a higher incidence of adverse events resulting in an average cost of $399.02. Comparatively, [[nifedipine]] had an average cost of $16.75<ref name="pmid17904969">{{cite journal| author=Hayes E, Moroz L, Pizzi L, Baxter J| title=A cost decision analysis of 4 tocolytic drugs. | journal=Am J Obstet Gynecol | year= 2007 | volume= 197 | issue= 4 | pages= 383.e1-6 | pmid=17904969 | doi=10.1016/j.ajog.2007.06.052 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17904969 }}</ref> | ||
|- | |- | ||
| colspan="2" | | | colspan="2" | | ||
=== '''Immune modulation''' === | ==='''Immune modulation'''=== | ||
|- | |- | ||
|'''Corticosteroids''' | |'''Corticosteroids''' | ||
Revision as of 06:14, 8 August 2022
|
Capillary leak syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Capillary leak syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Capillary leak syndrome cost-effectiveness of therapy |
|
FDA on Capillary leak syndrome cost-effectiveness of therapy |
|
CDC on Capillary leak syndrome cost-effectiveness of therapy |
|
Capillary leak syndrome cost-effectiveness of therapy in the news |
|
Blogs on Capillary leak syndrome cost-effectiveness of therapy |
|
Risk calculators and risk factors for Capillary leak syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
Cost-effective therapy
| Treatment | Mechanism of Action |
|---|---|
Endothelial signal transduction | |
| Bevacizumab |
|
| Epoprostenol |
|
| Theophylline + Terbutaline |
|
Immune modulation | |
| Corticosteroids | |
| Infliximab | |
| IVIG | |
| Plasmapheresis | |
References
- ↑ "Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer". Am Health Drug Benefits. 8 (Spec Issue): 10–2. 2015. PMC 4570073. PMID 26380601.
- ↑ Petros AJ, Turner SC, Nunn AJ (1995). "Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension". J Pharm Technol. 11 (4): 163–6. doi:10.1177/875512259501100409. PMID 10144080.
- ↑ Jubran A, Gross N, Ramsdell J, Simonian R, Schuttenhelm K, Sax M; et al. (1993). "Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study". Chest. 103 (3): 678–84. doi:10.1378/chest.103.3.678. PMID 8449051.
- ↑ Hayes E, Moroz L, Pizzi L, Baxter J (2007). "A cost decision analysis of 4 tocolytic drugs". Am J Obstet Gynecol. 197 (4): 383.e1–6. doi:10.1016/j.ajog.2007.06.052. PMID 17904969.